NCT04274426
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04274426
Title Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRalpha) High Recurrent Ovarian Cancer (MIROVA)
Acronym MIROVA
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors AGO Research GmbH
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU

Facility Status City State Zip Country Details
Charite - Universitätsmedizin Berlin Berlin Germany Details
Städtisches Klinikum Dessau Dessau Germany Details
Universitätsklinikum Carl-Gustav-Carus an der Technischen Universität Dresden Dresden Germany Details
Evangelische Kliniken-Essen-Mitte Essen Germany Details
Universitätsklinikum Frankfurt Frankfurt Germany Details
Mammazentrum HH am Krankenhaus Jerusalem Hamburg Germany Details
Universitätsklinikum Hamburg Eppendorf Hamburg Germany Details
Medizinische Hochschule Hannover Hanover Germany Details
ViDia Christliche Kliniken Karlsruhe Karlsruhe Germany Details
St. Elisabeth-Krankenhaus GmbH Köln-Hohenlind Germany Details
Helios Klinikum Krefeld Krefeld Germany Details
Klinikum Mannheim Mannheim Germany Details
OnkoNet Marburg GmbH Marburg Germany Details
LMU Klinikum München Germany Details
Rotkreuzklinikum München München Germany Details
TU München, Klinikum recht der Isar München Germany Details
Universitätsklinikum Münster Münster Germany Details
Klinikum Südstadt Rostock Rostock Germany Details
UniversitätsklinikumUlm Ulm Germany Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field